A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma
2020; AlphaMed Press; Volume: 25; Issue: 10 Linguagem: Inglês
10.1634/theoncologist.2020-0440
ISSN1549-490X
AutoresMarc Roth, Dana B. Cardin, Erkut Borazanci, Margaux Steinbach, Vincent J. Picozzi, Alexander Rosemury, Raymond Wadlow, Robert A. Newman, Jordan Berlin,
Tópico(s)Hepatocellular Carcinoma Treatment and Prognosis
ResumoThis trial evaluating a novel plant extract, PBI-05204, did not meet its primary endpoint of overall survival but did show signals of efficacy in heavily pretreated mPDA. PBI-05204 was generally well tolerated, with the most common side effects related to treatment being vomiting (23.7%), nausea (18.4%), decreased appetite (18.4%), and diarrhea (15.8%). Additional trials are needed to explore the role of PBI-05204 in cancer treatment.
Referência(s)